^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ifabotuzumab (KB004)

    i
    Other names: KB004 , KB-004
    Company:
    Humanigen, Olivia Newton-John Cancer Research Institute
    Drug class:
    EPH receptor inhibitor, EphA3 inhibitor
    Related drugs:
    3years
    A Trial of KB004 in Patients With Glioblastoma (clinicaltrials.gov)
    P1, N=12, Completed, Olivia Newton-John Cancer Research Institute | Active, not recruiting --> Completed
    Clinical • Trial completion
    |
    EPHA3 (EPH receptor A3)
    |
    ifabotuzumab (KB004)
    over3years
    A Trial of KB004 in Patients With Glioblastoma (clinicaltrials.gov)
    P1, N=12, Active, not recruiting, Olivia Newton-John Cancer Research Institute | Trial completion date: Apr 2021 --> Sep 2021
    Clinical • Trial completion date
    |
    EPHA3 (EPH receptor A3)
    |
    ifabotuzumab (KB004)